JP2016113461A5 - - Google Patents

Download PDF

Info

Publication number
JP2016113461A5
JP2016113461A5 JP2015243831A JP2015243831A JP2016113461A5 JP 2016113461 A5 JP2016113461 A5 JP 2016113461A5 JP 2015243831 A JP2015243831 A JP 2015243831A JP 2015243831 A JP2015243831 A JP 2015243831A JP 2016113461 A5 JP2016113461 A5 JP 2016113461A5
Authority
JP
Japan
Prior art keywords
phenyl
dimorpholin
piperidin
dimethylamino
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015243831A
Other languages
English (en)
Japanese (ja)
Other versions
JP6420753B2 (ja
JP2016113461A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016113461A publication Critical patent/JP2016113461A/ja
Publication of JP2016113461A5 publication Critical patent/JP2016113461A5/ja
Application granted granted Critical
Publication of JP6420753B2 publication Critical patent/JP6420753B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015243831A 2014-12-17 2015-12-15 製剤 Active JP6420753B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462093060P 2014-12-17 2014-12-17
US62/093,060 2014-12-17
US201562250633P 2015-11-04 2015-11-04
US62/250,633 2015-11-04

Publications (3)

Publication Number Publication Date
JP2016113461A JP2016113461A (ja) 2016-06-23
JP2016113461A5 true JP2016113461A5 (cg-RX-API-DMAC7.html) 2018-05-10
JP6420753B2 JP6420753B2 (ja) 2018-11-07

Family

ID=54937330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015243831A Active JP6420753B2 (ja) 2014-12-17 2015-12-15 製剤

Country Status (25)

Country Link
US (2) US10172942B2 (cg-RX-API-DMAC7.html)
EP (1) EP3233054B1 (cg-RX-API-DMAC7.html)
JP (1) JP6420753B2 (cg-RX-API-DMAC7.html)
KR (1) KR102016822B1 (cg-RX-API-DMAC7.html)
CN (1) CN107205923B (cg-RX-API-DMAC7.html)
AU (1) AU2015365497B2 (cg-RX-API-DMAC7.html)
CA (1) CA2915199C (cg-RX-API-DMAC7.html)
CY (1) CY1124527T1 (cg-RX-API-DMAC7.html)
DK (1) DK3233054T3 (cg-RX-API-DMAC7.html)
ES (1) ES2881214T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211446T1 (cg-RX-API-DMAC7.html)
HU (1) HUE055928T2 (cg-RX-API-DMAC7.html)
IL (1) IL252158B (cg-RX-API-DMAC7.html)
LT (1) LT3233054T (cg-RX-API-DMAC7.html)
MX (1) MX380172B (cg-RX-API-DMAC7.html)
NZ (1) NZ731518A (cg-RX-API-DMAC7.html)
PL (1) PL3233054T3 (cg-RX-API-DMAC7.html)
PT (1) PT3233054T (cg-RX-API-DMAC7.html)
RS (1) RS62337B1 (cg-RX-API-DMAC7.html)
RU (1) RU2672875C1 (cg-RX-API-DMAC7.html)
SG (1) SG11201703826TA (cg-RX-API-DMAC7.html)
SI (1) SI3233054T1 (cg-RX-API-DMAC7.html)
TW (1) TWI660729B (cg-RX-API-DMAC7.html)
WO (1) WO2016097949A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703764B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3672571T (lt) 2017-08-25 2021-12-10 Pfizer Inc. Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą
US12109308B2 (en) * 2018-06-07 2024-10-08 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yljcarbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
KR20240040768A (ko) 2021-07-26 2024-03-28 셀퀴티 인크. 암의 치료에 사용하기 위한 1-(4-{[4-(디메틸아미노)피페리딘-1-일]카르보닐}페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아 (게다톨리십) 및 그의 조합물
WO2025128712A1 (en) 2023-12-12 2025-06-19 Celcuity Inc. Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea
US20260053814A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU2006251429A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising a diaryl urea compound and a PI3, AKT kinase or mTOR inhibitors (rapamycins) for cancer treatment
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
DE202008001253U1 (de) * 2008-01-28 2008-04-10 Mirror Image Ag Bildanzeigegerät
MY155653A (en) 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
ES2533788T3 (es) * 2008-05-30 2015-04-14 Genentech, Inc. Compuestos inhibidores de PI3K de tipo purina y métodos de uso
WO2010096619A1 (en) * 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
US9757432B2 (en) * 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
JP6309610B2 (ja) * 2013-03-14 2018-04-11 アブラクシス バイオサイエンス, エルエルシー 膀胱がんを処置する方法
EP3116547B1 (en) * 2014-03-14 2019-06-05 Pfizer Inc Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same

Similar Documents

Publication Publication Date Title
RU2734236C2 (ru) Композиции бендамустина и циклополисахарида
BR112016021130A2 (pt) Nanopartículas terapêuticas, composição farmacêutica compreendendo as referidas nanopartículas, processo para a preparação e uso das mesmas
FI3769781T3 (fi) Stabiili anti-ifnar1-formulaatio
JP2015231997A5 (cg-RX-API-DMAC7.html)
MY182282A (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
MX2018004376A (es) Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
RU2014101036A (ru) Стабилизированная композиция вориконазола
WO2016184576A3 (en) Dry powder composition comprising long-chain rna
FI3484446T3 (fi) Vasta-ainekoostumuksia
PL205936B1 (pl) Farmaceutyczny preparat zawierający termozolomid oraz sposób jego wytwarzania
CA2945201C (en) Vaccine compositions
JP2015134763A5 (cg-RX-API-DMAC7.html)
WO2013089394A3 (ko) 고분자 나노입자 수용액 조성물 및 그 제조방법
JP2016522243A5 (cg-RX-API-DMAC7.html)
JP2013527832A5 (cg-RX-API-DMAC7.html)
HRP20211446T1 (hr) Formulacije inhibitora pi3k/mtor za intravensko davanje
FI3685847T3 (fi) Komplementtiaktiivisuuden modulaattoreita
RU2018117935A (ru) Водная композиция, содержащая дантролен
JP2016027060A5 (cg-RX-API-DMAC7.html)
BR112014020930A2 (pt) método para produzir uma formulação seca de um agente biofármaco, e, formulação de um agente biofármaco
RU2017102325A (ru) Препарат рокурония с улучшенной стабильностью
RU2016129193A (ru) Составы на основе берберина и их применение
EP4249069A3 (en) Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
JP2015526463A5 (cg-RX-API-DMAC7.html)
FI3331516T3 (fi) Ropivakaiinihydrokloridin hyperbaarinen liuosinjektio ja menetelmä sen valmistamiseksi